How the FDA Handles GI Drug Safety

被引：0

|

作者：

Lewis, James H. ^{[1
]}

机构：

[1] Georgetown Univ, Div Gastroenterol, Med Ctr, Washington, DC 20007 USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2012年 / 107卷 / 08期

关键词：

ISCHEMIC COLITIS; RISK;

D O I：

10.1038/ajg.2012.175

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：1264 / 1264

页数：1

相关论文

共 50 条

[31] Report on Drug Safety and the US FDA by the Institute of Medicine
Anthony W. Fox
International Journal of Pharmaceutical Medicine, 2006, 20 (5) : 289 - 291
[32] US FDA enhancing postmarketing drug safety surveillance
Reactions Weekly, 2019, 1780 (1) : 3 - 3
[33] Access and Safety-The FDA Drug Approval Conundrum
Good, Chester B.
Peasah, Samuel K.
JAMA NETWORK OPEN, 2024, 7 (07)
[34] US FDA 2009 drug safety warnings analysed
Reactions Weekly, 2012, 1388 (1) : 4 - 4
[35] FDA sets policies to enhance drug security and safety
Wechsler, Jill
Pharmaceutical Technology, 2015, 39 (02) : 16 - 19
[36] New FDA guidance on drug safety information communication
Reactions Weekly, 2007, 1142 (1) : 2 - 2
[37] FDA needs more sophisticated approach to drug safety
Christie, B
BRITISH MEDICAL JOURNAL, 2005, 330 (7501): : 1166 - 1166
[38] US FDA Enhancing Postmarketing Drug Safety Surveillance
不详
PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 64 - 64
[39] A Difficult Balance - Pain Management, Drug Safety, and the FDA
Woodcock, Janet
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (22): : 2105 - 2107
[40] FDA planning automated system for better drug safety
Lane, Kenneth W.
TELEMEDICINE JOURNAL AND E-HEALTH, 2006, 12 (06): : 611 - 612

← 1 2 3 4 5 →